Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
General Catalyst is a venture capital firm that invests other people's money into early-stage and growing startups, mostly in healthcare, fintech, and software.
General Catalyst is a venture capital firm. It raises big pools of money from pension funds, endowments, wealthy families, and other institutions, then writes checks to startups it believes can become huge businesses. The startups get cash to hire engineers, build products, and grow fast. In exchange, General Catalyst gets an ownership stake — usually preferred stock — that it hopes will be worth many times the original check if the company succeeds.
The firm is best known for backing software and internet companies early, and it has since pushed hard into healthcare and fintech. Its healthcare arm, called Health Assurance, invests in digital health, care delivery, and payment companies, betting that software can make American medicine cheaper and more convenient. On the fintech side, it has backed payments, banking, and insurance startups. The bet is the same across all three areas: find a founder attacking a giant, slow-moving market with software, get in early, and hold on. General Catalyst makes money in the standard venture way. It charges its investors a management fee — typically a small percentage of the money under management each year — and keeps a share of the profits, usually around 20%, once investments pay off. That profit share, called carried interest, is where the real money is. It also runs later-stage and "creation" strategies, where it helps found or seed companies itself rather than waiting for founders to walk in the door.
The business is risky by design. Most startups fail, so a fund's returns depend on a handful of enormous winners paying for everything else. General Catalyst's edge is its network and reputation: hot founders take its calls, and its portfolio companies help each other. Its main competitors are other top-tier venture firms — Andreessen Horowitz and Sequoia Capital among them — plus corporate venture arms and, in healthcare, private equity. The firm's fortunes rise and fall with the startup funding cycle, which has been bumpy since 2022 as higher interest rates cooled the easy money that once flowed to unproven companies.
Saved answer · last researched 15 Nov 2026